Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs.
about
Management of women with multiple sclerosis through pregnancy and after childbirthLinking databases on perinatal health: a review of the literature and current practices in EuropeMultiple sclerosis and pregnancy: maternal considerations.Multiple sclerosis and pregnancy: experience from a nationwide database in Germany.Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.Specific aspects of modern life for people with multiple sclerosis: considerations for the practitionerFemale reproductive issues in multiple sclerosis.Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance.Current recommendations for multiple sclerosis treatment in pregnancy and puerperium.Disease modification in multiple sclerosis: an update.Glatiramer acetate to treat multiple sclerosis during pregnancy and lactation: a safety evaluation.Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs.Evaluating the Safety of Medication Exposures During Pregnancy: A Case Study of Study Designs and Data Sources in Multiple Sclerosis.Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry.Glatiramer acetate during early pregnancy: A prospective cohort study.Association between beta-interferon exposure and hospital events in multiple sclerosis.Labor induction and augmentation in women with multiple sclerosis.Birth outcomes in newborns fathered by men with multiple sclerosis exposed to disease-modifying drugs.
P2860
Q26748594-A1087E94-7067-427B-8EF1-C6667C64D8A2Q29353625-F1BD0777-A86C-4002-9567-10579ABB7FECQ34639869-5FB4810B-5406-4110-993C-972F69502FA9Q36220437-562874CC-8B9B-4E6E-9CDB-4A83361400D2Q36475245-D60418B8-7B1C-4C39-8DC9-D1EEDBD65ECFQ37599577-7E103F0E-6591-4350-A612-34071B7C2ABBQ38021743-5599D4E7-8BA6-4DCF-9239-E8257E22D104Q38085336-85D0DF2D-229B-4A95-94C9-CDF88B456CD2Q38125249-63663A57-DDE9-409F-84D5-5C157DB9E23FQ38150823-DD0307F0-4623-4731-B336-E61CCAA82483Q38245158-672201A5-E223-4E2A-9FA3-FAB83869ED05Q38379249-3C332807-3F06-4ED5-9C1B-5821044B7124Q38653267-01AAEA06-6552-4F35-B657-20F464458B9BQ39964998-F99C0DBB-125F-486A-BDC5-C5696D97E19CQ40120131-4E70BC48-612C-4C64-AF1B-4BEA50268E64Q43995853-4F8A289F-6765-4347-8952-0A77477FD305Q44028593-4B9E7D91-0EFE-4C54-AD74-D704E4D11D11Q48543545-256FF8B6-849B-4926-A0B7-FA0E22B35EF9
P2860
Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs.
@en
Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs.
@nl
type
label
Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs.
@en
Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs.
@nl
prefLabel
Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs.
@en
Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs.
@nl
P2093
P2860
P356
P1476
Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs
@en
P2093
P2860
P304
P356
10.1177/1352458511422244
P577
2011-09-13T00:00:00Z